Sugi Predict

Sugi Predict / Compounds / SCHEMBL239130

SCHEMBL239130

SCHEMBL239130

CC(C)(C)OC(=O)N1CCCC1C(N)=O

nearest known ligand 0.59

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.59
▸ SMN1; SMN2 Q16637 1/20 0.52
▸ NPC1 O15118 1/20 0.52
▸ LMNA P02545 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ UCHL1 P09936 2/20 0.48
▸ SCN4A P35499 1/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ SCN5A Q14524 1/20 0.44
▸ SCN3A Q9NY46 1/20 0.44
▸ EPHX2 P34913 1/20 0.44
▸ USP30 Q70CQ3 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL240483 1.00 HSD17B10 (0.59) HSD17B10SMN1; SMN2NPC1LMNANPSR1
SCHEMBL2225858 1.00 HSD17B10 (0.59) HSD17B10SMN1; SMN2NPC1LMNANPSR1
SCHEMBL1478166 0.95 HSD17B10 (0.55) HSD17B10SMN1; SMN2NPC1LMNANPSR1
SCHEMBL1478184 0.95 HSD17B10 (0.55) HSD17B10SMN1; SMN2NPC1LMNANPSR1
SCHEMBL82116 0.95 HSD17B10 (0.55) HSD17B10SMN1; SMN2NPC1LMNANPSR1
SCHEMBL1398934 0.90 HSD17B10 (0.48) HSD17B10SMN1; SMN2NPC1LMNANPSR1
SCHEMBL29755212 0.90 HSD17B10 (0.48) HSD17B10SMN1; SMN2NPC1LMNANPSR1
SCHEMBL5069216 0.90 HSD17B10 (0.48) HSD17B10SMN1; SMN2NPC1LMNANPSR1
SCHEMBL31638601 0.87 HSD17B10 (0.57) HSD17B10SMN1; SMN2NPC1LMNANPSR1
SCHEMBL2636790 0.87 HSD17B10 (0.57) HSD17B10SMN1; SMN2NPC1LMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116693439-A Synthesis method of (R) -N-methyl-1- (pyrrolidine-2-yl) methylamine 南通敏言生物医药科技有限公司 2023-09-05 — — CN claimed
EP-3438106-A1 ANTI-VIRAL COMPOUNDS AbbVie Ireland Unlimited Company (IE) 2019-02-06 — — EP claimed
US-20190015402-A1 Anti-Viral Compounds ABBVIE INC. (US) 2019-01-17 — — US claimed
EP-2606038-B1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL MYERS SQUIBB CO (US) 2016-01-13 — — EP claimed
US-8765944-B2 Compounds for the treatment of hepatitis C BRISTOL-MYERS SQUIBB COMPANY (US) 2014-07-01 — — US claimed
EP-2606038-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C Bristol-Myers Squibb Company (US) 2013-06-26 — — EP claimed
US-20120213729-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2012-08-23 — — US claimed
WO-2012024373-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2012-02-23 — — WO claimed
WO-2026098560-A2 BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF 上海翰森生物医药科技有限公司 2026-05-15 — — WO disclosed
WO-2025137267-A1 MODULATORS OF TNF-ALPHA ACTIVITY FORWARD THERAPEUTICS, INC. (US) 2025-06-26 — — WO disclosed
US-20240092739-A1 COMPOUNDS AND METHODS OF USE VENTHERA, INC. 2024-03-21 — — US disclosed
WO-2023239645-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-12-14 — — WO disclosed
US-20230285378-A1 Anti-Viral Compounds ABBVIE INC. (US) 2023-09-14 — — US disclosed
EP-3481845-B1 C17, C20, AND C21 SUBSTITUTED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE SAGE THERAPEUTICS INC (US) 2023-09-13 — — EP disclosed
US-20080004263-A1 Ligands of Follicle Stimulating Hormone Receptor and Methods of Use Thereof ARENA PHARMACEUTICALS, INC. 2008-01-03 — — US disclosed
US-20070259926-A1 mGluR5 modulators III ASTRAZENECA AB (SE) 2007-11-08 — — US disclosed
US-20070259862-A1 MGluR5 modulators I ASTRAZENECA AB (SE) 2007-11-08 — — US disclosed
US-20070244328-A1 Organocatalysts and Methods of Use in Chemical Synthesis STC.UNM (US) 2007-10-18 — — US disclosed
WO-2006007586-A1 ORGANOCATALYSTS AND METHODS OF USE IN CHEMICAL SYNTHESIS SCIENCE & TECHNOLOGY CORPORATION @ UNM (US) 2006-01-19 — — WO disclosed
WO-2005087765-A1 LIGANDS OF FOLLICLE STIMULATING HORMONE RECEPTOR AND METHODS OF USE THEREOF ARENA PHARMACEUTICALS, INC. (US) 2005-09-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244328-A1 Organocatalysts and Methods of Use in Chemical Synthesis SCO2, CBR1, CBR3 HSD17B10 424/4885SMN1; SMN2 3982/4885NPC1 902/4885
US-20070259862-A1 MGluR5 modulators I GRM5, GRM1, GRIK5 HSD17B10 2742/4885SMN1; SMN2 1207/4885NPC1 705/4885
US-20070259926-A1 mGluR5 modulators III GRM5, GRM3, GRIK5 HSD17B10 2740/4885SMN1; SMN2 1346/4885NPC1 924/4885
US-20230285378-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS HSD17B10 2002/4885SMN1; SMN2 4141/4885NPC1 81/4885
US-20080004263-A1 Ligands of Follicle Stimulating Hormone Receptor and Methods of Use Thereof FSHR, GNRHR, LHCGR HSD17B10 522/4885SMN1; SMN2 4798/4885NPC1 1822/4885
US-20120213729-A1 Compounds for the Treatment of Hepatitis C HAVCR2, SLC10A1, HCCS HSD17B10 638/4885SMN1; SMN2 2944/4885NPC1 30/4885
US-20190015402-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS HSD17B10 2002/4885SMN1; SMN2 4141/4885NPC1 81/4885
US-20240092739-A1 COMPOUNDS AND METHODS OF USE AIFM2, SLC40A1, GPX4 HSD17B10 986/4885SMN1; SMN2 2634/4885NPC1 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.